Phase 4 Parkinson's Disease Trial, Not Yet Recruiting NCT07384429 Sponsor: YangPan Condition: Parkinson's Disease
Back to Parkinsons Disease

Phase 4 Parkinson's Disease Trial, Not Yet Recruiting

NCT07384429
Not Yet Recruiting Phase 4

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People who are aged 50 years or older.
  • People who have been diagnosed with idiopathic Parkinson's disease according to a specific set of clinical diagnostic criteria (the Movement Disorder Society 2015 guidelines), with a disease severity rating between stage 1 and stage 4 on a standard scale called Hoehn & Yahr.
  • People whose Parkinson's disease was diagnosed at least 2 years ago, whose condition is currently stable, and who are able to take part in the study's assessments and activities.
  • People who have also been diagnosed with insomnia disorder according to a standard mental health diagnostic guide (DSM-5), and who score 15 or higher on a standard insomnia questionnaire called the Insomnia Severity Index.
  • People who have been on the same medication regimen for at least 4 weeks before the study begins.
  • People who have signed a consent form agreeing to take part, either themselves or through a legal guardian, after being given the opportunity to understand what the study involves.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who have a history of, or have been diagnosed with, a serious psychiatric condition such as depression, anxiety disorders, schizophrenia, or bipolar disorder.
  • People who have a diagnosed neurological condition (assessed by self-report), including conditions that may raise pressure in the brain, brain tumours, a history of stroke, a mini-stroke within the past 2 years, a brain aneurysm, dementia, or multiple sclerosis.
  • People with significant memory or thinking difficulties, indicated by a score below 24 on a standard cognitive test called the Mini-Mental State Examination, or people who are unable to complete questionnaires on their own.
  • People who have chronic obstructive pulmonary disease (a long-term lung condition also known as COPD), or any history of breathing problems during sleep, such as sleep apnea.
  • People who nap during the day for 1 hour or more, on 3 or more days per week.
  • People who regularly consume caffeine.
  • People who have used any medication that acts on orexin receptors (a type of brain signalling system) in the past 3 months.
  • People who have a history of cataplexy (sudden muscle weakness) or who are known to have low orexin levels.
  • People who are unable to read or understand Chinese.
  • People who have used any other sleep-promoting medications in the past 3 months.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 13 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Phone: 02582263671

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Phase 4
Sponsor
YangPan
Registry
ClinicalTrials.gov
Start date
19 August 2026
Est. completion
1 December 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Changes in the scores of the Parkinson's Disease Sleep Scale (PDSS); Changes in the scores of Part III of the Unified Parkinson's Disease Rating Scale (UPDRS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov